Precigen, Inc.
- Open
- 5.65
- Day high
- 5.67
- Day low
- 5.38
- Prev close
- 5.70
- Volume
- 4.2M
- Mkt cap
- $1.9B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 95.1
- P/S
- 60.9
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.1M over the last 3 months (0 open-market buys, 5 sales)
- 🏛Institutions accumulating (13F)
Precigen, Inc. (PGEN) is a Healthcare company listed on NASDAQ. The stock is up 293% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 5 sales (SEC Form 4).
Precigen, Inc. (PGEN) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PGEN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-0.03 | $-0.02 | +33.3% | $23M | +11.8% |
| Mar 25, 2026 | $-0.10 | $-0.01 | +90.0% | $5M | -45.6% |
| Nov 13, 2025 | $-0.08 | $-0.11 | -37.5% | $3M | -64.7% |
| Aug 12, 2025 | $-0.14 | $-0.11 | +21.4% | $856000 | -8.3% |
| Mar 19, 2025 | $-0.06 | $-0.04 | +33.3% | $1M | +62.3% |
| Nov 14, 2024 | $-0.08 | $-0.09 | -12.5% | $953000 | -26.7% |
| Aug 14, 2024 | $-0.09 | $-0.10 | -11.1% | $717000 | -44.0% |
| Feb 13, 2024 | $-0.08 | $-0.13 | -62.5% | $1M | — |
| Nov 9, 2023 | $-0.08 | $-0.08 | +0.0% | $1M | -18.9% |
| Mar 6, 2023 | $-0.10 | $-0.11 | -10.0% | $2M | -71.6% |
| Nov 9, 2022 | $0.10 | $-0.04 | -140.0% | $17M | +514.8% |
| Mar 1, 2022 | $-0.14 | $-0.13 | +7.1% | $24M | -0.3% |
PGEN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 1, 2026 | Lehr Donald P.officer: Chief Legal Officer | Sell | 29,131 | $4.36 |
| Jun 1, 2026 | Sabzevari Helenofficer: President and CEO | Sell | 119,250 | $4.36 |
| Jun 1, 2026 | Thomasian Harry Jr.officer: Chief Financial Officer | Sell | 41,884 | $4.36 |
| Jun 1, 2026 | Tennant Philofficer: Chief Commercial Officer | Sell | 30,272 | $4.36 |
| Jun 1, 2026 | Shah Rutul Rofficer: Chief Operating Officer | Sell | 42,703 | $4.36 |
| May 27, 2026 | Sabzevari Helenofficer: President and CEO | Option | 250,000 | — |
| May 27, 2026 | Tennant Philofficer: Chief Commercial Officer | Option | 62,500 | — |
| May 27, 2026 | Lehr Donald P.officer: Chief Legal Officer | Option | 62,500 | — |
| May 27, 2026 | Thomasian Harry Jr.officer: Chief Financial Officer | Option | 87,500 | — |
| May 27, 2026 | Shah Rutul Rofficer: Chief Operating Officer | Option | 90,000 | — |
| Apr 22, 2026 | Thomasian Harry Jr.officer: Chief Financial Officer | Grant | 399,000 | $4.11 |
| Apr 22, 2026 | Tennant Philofficer: Chief Commercial Officer | Grant | 385,000 | $4.11 |
| Apr 22, 2026 | Lehr Donald P.officer: Chief Legal Officer | Grant | 107,000 | — |
| Apr 22, 2026 | Sabzevari Helenofficer: President and CEO | Grant | 1,366,000 | $4.11 |
| Apr 22, 2026 | Shah Rutul Rofficer: Chief Operating Officer | Grant | 395,000 | $4.11 |
Source: PGEN SEC Form 4 filings, latest Jun 1, 2026. For informational purposes only — not investment advice.
See the full PGEN insider & 13F page →Precigen, Inc. company profile
Overview
Precigen, Inc. (NASDAQ:PGEN) is a biotechnology company founded in 1998 and headquartered in Germantown, Maryland. Originally known as Intrexon Corporation, the company rebranded to Precigen in January 2020 to better reflect its focus on precision gene and cellular therapies. The company has evolved from a broader synthetic biology platform into a specialized developer of next-generation gene and cellular therapies, with particular emphasis on rare diseases and cancer treatments. Precigen has undergone significant strategic restructuring in recent years, streamlining operations to focus on its most promising therapeutic candidates while divesting non-core assets.
Business
Precigen operates in the biotechnology sector, specifically developing gene and cellular therapies using proprietary synthetic biology platforms. The company's core business revolves around creating genetically engineered treatments that can modify or replace defective genes to treat diseases at their root cause, rather than just managing symptoms. The company's primary technology platforms include AdenoVerse, which uses engineered adenoviral vectors (modified viruses) to deliver therapeutic genes directly into patient cells, and UltraCAR-T, which creates genetically modified immune cells that can better recognize and destroy cancer cells. Gene therapy works by introducing functional genes into a patient's cells to correct genetic defects or provide new cellular functions, while CAR-T (Chimeric Antigen receptor T-cell) therapy involves extracting a patient's immune cells, genetically modifying them to better target cancer, and then reinfusing them. Precigen's business is primarily focused on two main therapeutic areas: 1) Rare diseases, particularly Recurrent Respiratory Papillomatosis (RRP) through their lead candidate PRGN-2012, which represents the majority of their current commercial focus and near-term revenue potential, and 2) Cancer treatments using their UltraCAR-T platform for various blood cancers and solid tumors, including acute myeloid leukemia and ovarian cancer. The company also maintains smaller programs in other areas including HPV-related cancers and autoimmune diseases.
Revenue model
Precigen's business model is built around developing proprietary gene and cellular therapies and monetizing them through direct product sales to healthcare providers and patients. As a clinical-stage biotechnology company, Precigen currently generates minimal revenue from product sales, with most income coming from research collaborations and licensing agreements. The company's primary revenue opportunity lies in PRGN-2012 for RRP treatment, which is expected to launch commercially in the second half of 2025 following anticipated FDA approval. The company's paying customers will primarily be hospitals, specialty clinics, and healthcare systems that treat patients with rare diseases and cancers. For RRP treatment, the target customers are the approximately 500 fellowship-trained otolaryngologists (ear, nose, and throat specialists) in the United States who treat an estimated 27,000 adult patients with this rare condition. Precigen plans to employ a focused commercial strategy with 15-20 sales representatives working with their partner EVERSANA. Several factors could significantly impact Precigen's margins and profitability. Positive factors include the company's focus on rare diseases with high unmet medical need, which typically command premium pricing due to limited treatment alternatives and smaller patient populations. The company is exploring value-based pricing models that tie payment to patient outcomes. However, negative factors include the high cost of manufacturing gene and cellular therapies, potential payer resistance requiring prior authorization processes, competition from existing treatments, and the substantial ongoing research and development costs required to advance their pipeline. Manufacturing costs for gene therapies are typically high due to complex production processes, specialized facilities, and stringent quality requirements, though Precigen's decentralized UltraCAR-T manufacturing approach may help reduce some costs.
Competitive moat
Precigen's competitive moat is relatively narrow and primarily based on its proprietary technology platforms and early-mover advantage in specific rare disease applications. The company's AdenoVerse platform using gorilla adenoviruses offers some differentiation through unique redosing capabilities, as these vectors may avoid the immune responses that limit repeat dosing with traditional human adenoviral vectors. Their UltraCAR-T platform's decentralized manufacturing approach, which enables overnight production of CAR-T therapies at multiple hospital sites, represents a potential operational advantage over centralized manufacturing models that require weeks of processing time. However, Precigen's moat faces significant challenges. The gene therapy and CAR-T therapy markets are highly competitive, with numerous well-funded biotechnology companies and pharmaceutical giants developing similar approaches. Large companies like Gilead, Novartis, and Bristol Myers Squibb have substantial resources and established CAR-T products, while gene therapy competitors include companies with deeper pockets and more advanced manufacturing capabilities. The regulatory environment is also challenging, with high development costs and lengthy approval processes that can be difficult for smaller companies to navigate. The company's strongest defensive position lies in their focus on rare diseases like RRP, where the small patient populations and high unmet medical need create natural barriers to entry. However, even in rare diseases, the moat is not insurmountable, as larger pharmaceutical companies may develop competing therapies or acquire smaller competitors. Precigen's intellectual property portfolio provides some protection, but the biotechnology industry is characterized by rapid innovation and the constant risk of technological obsolescence. Overall, while Precigen has some competitive advantages, its moat is relatively weak and vulnerable to well-funded competition.
Risks & safety
Precigen presents significant financial risks with a narrow margin of safety for investors. • **Cash Position**: $29.5 million in cash and short-term investments as of Q4 2024, with quarterly cash burn of approximately $16-25 million, providing runway into 2026 but requiring additional financing • **Debt Level**: Moderate debt-to-equity ratio of 0.14, indicating manageable debt burden relative to equity • **Solvency Risk**: High ongoing losses with net loss of $126.2 million in 2024 and negative free cash flow of $76.8 million, creating substantial dilution risk for equity holders • **Valuation Metrics**: Trading at negative P/E ratios due to losses, with price-to-book ratio of 7.8x indicating significant premium to tangible assets • **Revenue Generation**: Minimal current revenue of $3.9 million annually, with commercial revenue not expected until second half of 2025 • **Regulatory Risk**: Primary asset PRGN-2012 awaiting FDA approval with PDUFA date of August 27, 2025, creating binary outcome risk • **Market Concentration**: Heavy dependence on single lead asset for near-term value creation in small rare disease market of approximately 27,000 patients
Recent development
Over the past few years, Precigen has undergone a dramatic strategic transformation, evolving from a diversified synthetic biology company into a focused gene and cellular therapy developer. The most significant pivot occurred in 2024 when management reduced the workforce by over 20% and concentrated resources on their lead asset PRGN-2012 for Recurrent Respiratory Papillomatosis treatment. This strategic focus culminated in the submission of a Biologics License Application (BLA) to the FDA, which was accepted with priority review and a PDUFA date set for August 27, 2025. The company has made substantial progress in preparing for commercialization, partnering with EVERSANA for the commercial launch and hiring Phil Tennant as Chief Commercial Officer. Clinical results for PRGN-2012 have been compelling, showing a 51% complete response rate, 86% reduction in surgical procedures, and median response duration of 24 months. The FDA granted both Breakthrough Therapy and Orphan Drug designations, accelerating the development timeline. Simultaneously, Precigen has been streamlining its portfolio by pausing several programs including PRGN-3005 for ovarian cancer and PRGN-3007 for ROR1-positive tumors, while shutting down the ActoBio subsidiary. The company divested Trans Ova Genetics for $170 million in 2022, using proceeds to retire debt and extend cash runway. Recent financing activities include raising $79 million through preferred stock issuance in 2024, providing funding through the anticipated commercial launch. The UltraCAR-T platform continues to show promise with encouraging data in acute myeloid leukemia and autoimmune applications, though these programs remain in earlier development stages.
PGEN company profile · for informational purposes only — not investment advice.
Track PGEN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free